Why the study?
Are N-terminal pro-brain natriuretic peptide levels elevated in women with hypertensive disorders of pregnancy compared to normotensive women?
Are N-terminal pro-brain natriuretic peptide levels elevated in women with hypertensive disorders of pregnancy compared to normotensive women?
NT-proBNP is significantly elevated in hypertensive disorders of pregnancy and correlates with disease severity, suggesting its potential utility as a biomarker in this population.
Answers are grounded in this paper and cite their sources.
May support NT-proBNP as a biomarker in hypertensive pregnancy disorders; leaves open prospective validation before clinical use.
We tested the hypothesis that the cardiac biomarker N-terminal pro-brain natriuretic peptide would be elevated in hypertensive disorders of pregnancy, with an increase in levels of this biomarker across increasing gradations of disease severity. We performed a case-controlled study of women admitted to labor and delivery at the Hospital of the University of Pennsylvania between 24 and 42 weeks of gestation. Cases had hypertension that developed after 20 weeks of gestation, and controls were normotensive women presenting for delivery. N-terminal pro-brain natriuretic peptide levels were compared between cases ( N = 83) and controls ( N = 290). Cases were subclassified into gestational hypertension ( N = 20) and mild ( N = 15) and severe preeclampsia ( N = 48), and N-terminal pro-brain natriuretic peptide levels were compared between these subgroups. N-terminal pro-brain natriuretic peptide levels were higher in cases than in controls (81 pg/mL versus 37 pg/mL, P < 0.001), with a graded increase in levels from gestational hypertension (64 pg/mL) to preeclampsia (89 pg/mL) to severe preeclampsia (157 pg/mL; P < 0.001). Each log increase in N-terminal pro-brain natriuretic peptide doubled the risk of preeclampsia (odds ratio = 2.10 P < 0.001). N-terminal pro-brain natriuretic peptide levels were increased in hypertensive disorders of pregnancy and discriminate between subcategories of disease.
No takes yet. Share an insight, caveat, or question.
Moghbeli et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: